The Patent Finder

Samsung Biologics Co., Ltd.

46 patents currently held · Updated Nov 21, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
May 2031
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 3 fees due Feb 11 to 27, 2027 · next Feb 11
  • 1 fee due May 24, 2027
    The maintenance fee for Method of Treating Cancer Using Anti-C-Met Antibody and FGFR Inhibitor Combination Therapy (US 9,192,666) comes due May 24, 2027. Unpaid by Nov 24, 2027, it lapses early.
  • 2 fees due Jun 15, 2027
  • 1 fee due Jul 12, 2027
    The maintenance fee for Method of Treating Solid Cancers Using Anti-C-Met Antibody and Sorafenib Combination Therapy (US 9,233,155) comes due Jul 12, 2027. Unpaid by Jan 12, 2028, it lapses early.
  • 1 fee due Sep 15, 2027
    The maintenance fee for Method of Screening Antibodies with High Antigen Selectivity (US 9,285,371) comes due Sep 15, 2027. Unpaid by Mar 15, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,546,544Antibody Specifically Binding to C-Met and Methods of Use
In force
 · High confidence
In forceHigh confidence
US 8,563,696Antibody Specifically Binding to C-Met
In force
 · High confidence
In forceHigh confidence
US 8,987,425Pharmaceutical Composition for Preventing or Treating Cancer
In force
 · High confidence
In forceHigh confidence
US 8,859,507Protein Complex for Intracellular Delivery and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 8,501,917Anti C-Met Antibody and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,101,610Anti C-Met Humanized Antibody and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,394,367Antibody Specifically Binding to Epitope in Sema Domain of C-Met
In force
 · High confidence
In forceHigh confidence
US 9,777,072Protein Complex and Method of Preparing Same
In force
 · High confidence
In forceHigh confidence
US 9,213,031Use of CBL as Biomarker for Identifying Subject Suitable for Treatment with Anti-C-Met Antibody
In force
 · High confidence
In forceHigh confidence
US 9,213,032Use of LRIG1 as a Biomarker for Identifying a Subject for Application of Anti-C-Met Antibodies
In force
 · High confidence
In forceHigh confidence
10 of 46 patents shown.
Pro members see all 46.
Pro members: see all 46 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 1 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited